Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Abstract Background Anti-programmed cell death receptor-1 (PD-1) monotherapy is the standard treatment for metastatic melanoma in current. Camrelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody whose safety and efficacy have not been reported in advanced Asian melanoma patients. Methods This...

Full description

Bibliographic Details
Main Authors: Li Zhou, Xiaowen Wu, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan, Xuan Wang, Xue Bai, Siming Li, Xiaoting Wei, Juan Li, Qing Yang, Jun Guo, Chuanliang Cui
Format: Article
Language:English
Published: BMC 2022-05-01
Series:BMC Cancer
Subjects:
Camrelizumab
Advanced melanoma
Immunotherapy
Anti-PD-1 antibody
Online Access:https://doi.org/10.1186/s12885-022-09663-5

Internet

https://doi.org/10.1186/s12885-022-09663-5

Similar Items